We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
+11.13%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.52B
AUM Growth
-$86M
(-5.4%)
Cap. Flow
-$267M
Cap. Flow
% of AUM
-17.65%
Top 10 Holdings %
Top 10 Hldgs %
55.26%
Holding
50
New
2
Increased
13
Reduced
10
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LanzaTech
LNZA
|
+$106M |
| 2 |
4D Molecular Therapeutics
FDMT
|
+$13.6M |
| 3 |
Insmed
INSM
|
+$9.7M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$6.72M |
| 5 |
VERV
Verve Therapeutics
VERV
|
+$5.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stryker
SYK
|
+$195M |
| 2 |
Steris
STE
|
+$86.4M |
| 3 |
Boston Scientific
BSX
|
+$62.6M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
+$49.4M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 57.28% |
| 2 | Technology | 25.52% |
| 3 | Financials | 5.42% |
| 4 | Communication Services | 4.36% |
| 5 | Industrials | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
ASML
ASML
$596B
| $154M | 10.18% |
226,770
| – | – |
|
2
Salesforce
CRM
$154B
| $116M | 7.63% |
578,500
| – | – |
|
|
CYT
3
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $113M | 7.45% |
3,940,413
| – | – |
|
4
Brookfield
BN
$102B
| $82.1M | 5.42% |
3,763,245
| – | – |
|
5
Corcept Therapeutics
CORT
$9.98B
| $73.2M | 4.83% |
3,377,768
| – | – |
|
6
TSMC
TSM
$1.94T
| $66.1M | 4.36% |
710,780
| – | – |
|
7
Cable One
CABO
$237M
| $66.1M | 4.36% |
94,103
| – | – |
|
|
8
LanzaTech
LNZA
$59.9M
| $61.4M | 4.05% |
+158,148
| New | +$106M |
|
|
CTLT
9
DELISTED
CATALENT, INC.
CTLT
| $54.7M | 3.61% |
832,878
-800,000
| -49% | -$49.4M |
|
10
Alibaba
BABA
$276B
| $51.2M | 3.38% |
500,827
| – | – |
|
11
Disc Medicine
IRON
$2.81B
| $49.6M | 3.27% |
2,340,772
| – | – |
|
12
Apple
AAPL
$4.97T
| $48.7M | 3.21% |
295,280
-73,824
| -20% | -$10.9M |
|
13
Edgewise Therapeutics
EWTX
$4.28B
| $40.5M | 2.67% |
6,071,703
| – | – |
|
14
Mirum Pharmaceuticals
MIRM
$6.56B
| $40.5M | 2.67% |
1,684,193
| – | – |
|
|
ACLX
15
DELISTED
Arcellx
ACLX
| $37.7M | 2.49% |
1,225,000
-259,020
| -17% | -$7.86M |
|
16
BioMarin Pharmaceuticals
BMRN
$11.9B
| $35.7M | 2.36% |
367,380
+49,680
| +16% | +$5.15M |
|
|
VECT
17
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $30.7M | 2.03% |
3,610,461
+270,977
| +8% | +$2.23M |
|
18
Vaxcyte
PCVX
$7.65B
| $27.9M | 1.84% |
745,000
+20,000
| +3% | +$848K |
|
|
SGEN
19
DELISTED
Seagen Inc. Common Stock
SGEN
| $27.3M | 1.8% |
134,986
-75,014
| -36% | -$12M |
|
20
Alnylam Pharmaceuticals
ALNY
$38.3B
| $23.7M | 1.56% |
118,383
+6,383
| +6% | +$1.34M |
|
|
FOLD
21
DELISTED
Amicus Therapeutics
FOLD
| $23.2M | 1.53% |
2,095,900
| – | – |
|
|
22
Insmed
INSM
$22.4B
| $22.8M | 1.51% |
1,339,304
+499,304
| +59% | +$9.7M |
|
|
OKUR
23
OnKure Therapeutics
OKUR
$160M
| $20.5M | 1.35% |
343,038
| – | – |
|
|
BPMC
24
DELISTED
Blueprint Medicines
BPMC
| $20.2M | 1.33% |
448,804
+78,804
| +21% | +$3.55M |
|
|
25
Crinetics Pharmaceuticals
CRNX
$8.88B
| $17.7M | 1.17% |
1,100,000
+362,943
| +49% | +$6.72M |
|
Similar funds
HCA
GX
MP
FLII
IC
CCA
WCM
IA
Novo Holdings A/S's Q1 2023 Portfolio in Review
As of Q1 2023, Novo Holdings A/S held 50 positions worth $1.52B, down 5.4% from $1.6B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Novo Holdings A/S withdrew a net $267M in Q1 2023, closing 3 positions and reducing 10 holdings. Its most notable exit was Stryker, an estimated $195M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 70% a quarter earlier, followed by Technology and Financials.
Against the trend, Novo Holdings A/S opened a new position in LanzaTech worth $61.4M.
- Novo Holdings A/S's largest Q1 2023 buy was LanzaTech: 158,148 shares worth $61.4M.
- Novo Holdings A/S added most to Insmed in Q1 2023, an estimated $9.7M increase.
- Novo Holdings A/S's biggest Q1 2023 reduction was CATALENT, INC., cutting an estimated $49.4M.
- Novo Holdings A/S fully exited Stryker in Q1 2023, selling an estimated $195M.
- Novo Holdings A/S's ten largest holdings make up 55% of its $1.52B portfolio in Q1 2023.
- Novo Holdings A/S opened 2 new positions and closed 3 in Q1 2023.
- Novo Holdings A/S's portfolio value fell 5.4% quarter-over-quarter to $1.52B.
Based on Novo Holdings A/S's 13F filing for Q1 2023, filed 15 May 2023.